Healthcare · GLP-1Google News
CVS brings back coverage for Lilly's obesity drug Zepbound - Reuters
1 min read
The story
CVS Caremark is restoring coverage of Lilly's Zepbound after Lilly cut pricing, potentially opening access to millions of insured Americans. LLY has already ripped 4.1% on the news, raising the question of whether the move is fully priced or sets up a continued re-rating.
0 reads·0 theses
The case — both sides
Angle
↓ SHORT-4% target+3% stop5-10 trading days
Fade the LLY spike near-term — stock is up 4% on news already digested by the market, insiders are selling, and consensus is already Buy-heavy with no new price-target catalyst to drive further re-rating.
2 stocks · % change · 3 monthsaverage+37.0%
LLY+38.9%CVS+35.1%Average
Names in play
1
LLY35
2
CVS100
The house read
Fade the LLY spike near-term — stock is up 4% on news already digested by the market, insiders are selling, and consensus is already Buy-heavy with no new price-target catalyst to drive further re-rating.
Wrong ifA formal CVS formulary volume disclosure or an unexpected Medicare/PBM coverage domino (e.g., Express Scripts follows) could extend the rally and invalidate the fade quickly.
Published read · research, not advice